Stephanie joined Drug Discovery News as an Assistant Editor in 2021. She earned her PhD from the University of California Los Angeles in 2019 and has written for Discover Magazine, Quanta Magazine, and the Los Angeles Times. As an assistant editor at DDN, she writes about how microbes influence health to how art can change the brain. When not writing, Stephanie enjoys tap dancing and perfecting her pasta carbonara recipe.
Articles by Stephanie DeMarco, PhD
| 5 min read
Via a unique regulatory route in the UK, scientists found that a gene therapy restored vision in young kids with a very rare and severe retinal dystrophy.
| 6 min read
Larkspur Biosciences scientists develop drugs that make colorectal cancer tumors vulnerable to killing by the immune system and cell death pathways.
| 5 min read
IO Biotech’s two-pronged cancer vaccine targets tumors and the suppressive immune cells around them, demonstrating promising results in metastatic melanoma.
| 5 min read
Roche scientists developed novel bead technology to automate mass spectrometry, increasing clinician and patient access to this sensitive diagnostic technology.
| 3 min read
Backed by patient data and an AI platform, the BPGbio team presented promising results for a mitochondrial-targeted therapy in glioblastoma at AACR 2025.
| 4 min read
Cancer researchers in biotech and pharma highlight the clinical trials and developments they’re most excited about.
| 5 min read
Among the thrill of new results presented at the AACR 2025 conference, the specter of funding cuts to cancer research hung over the meeting.
| 3 min read
The team at DropGenie uses digital microfluidics to perform gene editing screens on small numbers of patient cells, accelerating the discovery of new drugs.
| 10 min read
Advances in GLP-1 research for diabetes and obesity, multiple sclerosis discoveries, and DNA editing are awarded in this year’s prestigious prize.
| 7 min read
A targeted interleukin-12 gene therapy plus chemotherapy increased survival in advanced ovarian cancer, setting the stage for a new first-line drug.
| 6 min read
ArsenalBio equips T cells with multiple weapons to identify, attack, and persist against tumors, bringing the power of CAR T cell technology to solid cancers.
| 6 min read
Sabrina Johnson at Daré Bioscience is redefining contraception with Ovaprene, a non-hormonal, monthly option for safe and effective birth control.
| 3 min read
A close encounter with a venomous critter sparked insight for communicating science in times of stress.
| 4 min read
As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
| 4 min read
Industry leaders name the clinical trials and developments they’re most excited to see in the new year.
Page 1 of 11 - 156 Total Items
